• Olio Labs

  Led · Equity · Mar 2025

  Olio Labs operates an AI-powered therapeutic design platform centered on a combination design engine (CoDE) that integrates human medical records and biological data, in‑vivo phenomic screening, and neural and endocrine circuit maps. The platform fuses computational methods with biological expertise to shift pharmaceutical research from a molecule-first to a patient-first approach. Olio Labs highlights AI-powered integration of biological expertise as a core capability of CoDE. Led by CEO David Tingley, the company plans to use the new capital to expand operations and advance its development efforts. Its advisory board includes industry veterans Patricia Martin, Michael Schwartz, and Hugh Reinhoff. The company announced the funding in March 2025. Olio Labs uses artificial intelligence and machine learning to design combination therapeutics that account for complex interactions among thousands of proteins. Their AI-driven compute-experiment platform can design and test trillions of combinations, which the company says has accelerated discovery fourfold and reduced costs by 90%. Olio Labs is focused on discovering combinations that can outperform best-in-class obesity drugs and has reported promising results in animal models, including significant appetite reduction with associated decreases in nausea. The platform targets both combinations of existing drugs and novel targets. The company was founded by Dr. David Tingley and Dr. Tom Roseberry, whose backgrounds include Harvard, New York University, and Neuralink, and the team is expanding to accelerate research. Olio Labs participated in Y Combinator’s S23 batch and recently attracted investment from ZAKA VC.

• Bioptimus

  Participated · Equity · Jan 2025

  Bioptimus is building large-scale foundational AI models trained on multimodal biological data to simulate biology from molecules to whole organisms and predict disease outcomes. The company launched H-Optimus-0, an open-source foundation model for pathology trained on millions of images to aid research and diagnosis of diseases such as cancer. Bioptimus plans to broaden its data sources across additional therapeutic areas and to deepen partnerships with pharmaceutical and biotech companies. It will leverage multimodal patient data amassed via ties to Owkin to train its models, while acknowledging the sensitivity and scale of the clinical data required. The company was founded last year by six co-founders, including CEO Jean-Philippe Vert and CTO Rodolphe Jenatton, and is based in France. Financially, Bioptimus has quickly raised capital, bringing total funding to $76M after its latest $41M round following a $35M seed raise. Bioptimus is building large foundational AI models tailored to biological and clinical data with the goal of improving disease diagnosis, precision medicine, and discovering new biomolecules. The company plans to train multimodal models on sensitive clinical datasets amassed through Owkin’s partnerships with academic hospitals. Bioptimus says building these biology models will be capital- and compute-intensive, requiring expensive GPUs and top AI researchers. The team includes Jean-Philippe Vert as co-founder and executive chairman (non-operational), Rodolphe Jenatton as CTO (formerly a senior research scientist at Google), and several co‑founders from Google DeepMind. Bioptimus has signed a partnership with Amazon Web Services to run model training in AWS data centers. The startup recently raised funding to begin model development and data work.

• Interface Biosciences

  Participated · Seed · Dec 2023

  Interface Biosciences has developed an AI and metabolomics-based discovery platform to identify bacterial natural products that modulate the immune system and reduce inflammation. The company is advancing therapeutic programs targeting inflammatory diseases such as inflammatory bowel disease and rheumatoid arthritis. Its lead program is a 44‑amino peptide derived from Ruminococcus gnavus that the company reports has wound-healing, anti-inflammatory, and antibiotic activity against pathogens including Clostridium difficile and Staphylococcus aureus. Initial data reportedly show the lead compound is stable and non-toxic, with in vivo studies slated to begin in January 2024. Interface was founded by Stanford PhDs Hannah C. Wastyk and Will Van Treuren and is based in Palo Alto. The company recently closed an oversubscribed $3 million seed round to advance its platform and programs.

• BioLoomics

  Participated · Seed · Sep 2023

  BioLoomics develops a human-cell directed evolution platform to discover and engineer antibodies that drive target degradation and other spatial activities. The company combines synthetic biology, computer vision–guided cell picking, imaging, robotics, and machine learning to search antibody design space at high throughput. BioLoomics says its platform enables testing of antibody designs ~10,000x more than legacy methods and is adaptable across a wide variety of target classes. The team intends to use its technology to create safer, more effective cancer therapeutics by manipulating intracellular antibody trafficking. With the new capital, BioLoomics will advance proprietary platform technology and antibody degrader programs, develop pre-clinical assets, and pursue strategic partnerships with large pharma. The company is headquartered in Colorado and is actively recruiting for CSO and CTO roles; Dr. Nick Saccomano recently joined as an Independent Board Director.

• Sonera

  Participated · Seed · Sep 2023

  Sonera develops sensing technology that non-invasively detects magnetic signals generated by neural activity to make brain and muscle activity easy to measure. Its first product is the S1 chip for muscle sensing, designed to enable a new class of consumer wearables and experiences based on muscle activity without direct skin contact. The S1 approach measures magnetic fields from electrical currents tied to neural activity, aiming to deliver high-fidelity signals for use cases such as advanced prosthetics control, continuous neuromuscular monitoring, biomarker discovery, and sports performance tracking. The company positions neural data as a broadly useful physiological signal—similar to heart rate or temperature—for personal computing, smart apparel, healthcare, and neurotherapeutics. Sonera is led by CEO Nishita Deka and intends to use new funding to advance accessibility of neural data across these applications. Financially, the company has raised $11M in this Seed round, bringing total funding to $20M.

No current team members are available.